Subscribe free

Intestine and Lower Gastrointestinal Tract ·

Total neoadjuvant therapy increases risk of breached mesorectal excision but reduces disease progression in rectal cancer

Total neoadjuvant therapy for rectal cancer is associated with higher rates of breached total mesorectal excision compared to standard long-course chemoradiation, but no significant differences in surgical mortality or major complications. However, it significantly lowers the risk of disease progression to an unresectable stage during neoadjuvant treatment. Further research is needed to identify patients who will benefit from this approach.

Journal Article by Lin W, Li C (…) Phang PT et 5 al. in Ann Surg

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

read the whole article in Ann Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →